Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology
* Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients. * Bi-centric with ETHOS center : ICM (Institut du Cancer de Montpellier) and ISC (Institut Sainte Catherine) Avignon * 500 patients will be included: * COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk * COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk
• Women ≥ 18 years old.
• Conservative breast cancer surgery or radical mastectomy.
• At least pN1 breast cancers, regardless breast cancer subtypes.
• Tumor negative margins.
• Indication of whole breast and node irradiation.
• Extension evaluation of disease will be proven negative (M0).
• Risk level of breast fibrosis identified by the centralized NovaGray RILA Breast® test
• Must be geographically accessible for follow-up.
• Written and dated informed consent.
• Affiliated to the French national social security system.